ArriVent BioPharma (AVBP) Enterprise Value (2023 - 2026)
ArriVent BioPharma (AVBP) reported Enterprise Value of -$326.4 million for Q1 2026, down 85.36% on a YoY basis from -$2.2 billion in Q1 2025, and down 4.33% sequentially from -$312.8 million in Q4 2025.
ArriVent BioPharma (AVBP) Enterprise Value (2023 - 2026) Analysis & Trends
ArriVent BioPharma (AVBP) has 4 years of Enterprise Value data on file, last reported at -$326.4 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value fell 85.36% year-over-year to -$326.4 million; the trailing twelve-month figure through Mar 2026 stood at -$326.4 million (down 85.36% YoY), and the FY2025 full-year result was -$312.8 million, down 42.93% from the prior year.
- Enterprise Value slipped to -$326.4 million in Q1 2026, from -$312.8 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$124.3 million in Q4 2023 to a low of -$493.0 million in Q3 2025.
- A 4-year average of -$278.6 million and a median of -$290.8 million in 2024 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value surged 44.52% in 2025 and slumped 85.36% in 2026, its largest moves.
- Tracing AVBP's Enterprise Value over 4 years: stood at -$124.3 million in 2023, then sank by 76.08% to -$218.9 million in 2024, then slumped by 42.93% to -$312.8 million in 2025, then declined by 4.33% to -$326.4 million in 2026.
- Business Quant data shows AVBP's Enterprise Value at -$326.4 million in Q1 2026, -$312.8 million in Q4 2025, and -$493.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | ArriVent BioPharma | 1.42 Bn | 1.42 Bn | - | -326.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -326.38 Mn |
| Dec 31, 2025 | -312.82 Mn |
| Sep 30, 2025 | -492.99 Mn |
| Jun 30, 2025 | -235.69 Mn |
| Mar 31, 2025 | -176.08 Mn |
| Dec 31, 2024 | -218.86 Mn |
| Sep 30, 2024 | -282.86 Mn |
| Jun 30, 2024 | -298.67 Mn |
| Mar 31, 2024 | -317.39 Mn |
| Dec 31, 2023 | -124.30 Mn |